Vimarsana
Biggest News Aggregation in the World

Page 41 - Ir Team News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Ir Team. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Ir Team Today - Breaking & Trending Today

Investegate |Etalon Group PLC Announcements | Etalon Group PLC: Etalon Announces Results of Rump Offering - Vimarsana News

Investegate |Etalon Group PLC Announcements | Etalon Group PLC: Etalon Announces Results of Rump Offering

  Not for publication or distribution, in whole or in part, directly or indirectly, in or into the United States, Canada, Australia or Japan, or in any other jurisdiction in which such publication or distribution would be prohibited by applicable law or regulation.   Nothing in this announcement should be interpreted as a term or condition of the offering referred to herein. No decision to purchase, subscribe for, otherwise acquire, sell or otherwise dispose of any securities referred to herein should be made on the basis of this announcement and must only be made on...

EQS-Adhoc: Orascom Development Holding AG announces its Egyptian Subsidiary (ODE)1Q 2021 Financial Results - Vimarsana News

EQS-Adhoc: Orascom Development Holding AG announces its Egyptian Subsidiary (ODE)1Q 2021 Financial Results

EQS-Adhoc: Orascom Development Holding AG: ODH announces its Egyptian Subsidiary (ODE)1Q 2021 Financial Results Orascom Development Holding AG announces its Egyptian Subsidiary (ODE)1Q 2021 Financial Results 10-May-2021 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 KR The issuer is solely responsible for the content of this announcement. Dear All, Orascom Development Egypt (ODE); the Largest Egyptian Subsidiary of Orascom Development Holding AG (ODH), has reported its 1Q 2021 earnings today. Please find the earnings release along with the presentation under the link ...

EQS-Adhoc: Orascom Development Holding AG: ODH announces its Egyptian Subsidiary (ODE)1Q 2021 Financial Results - Vimarsana News

EQS-Adhoc: Orascom Development Holding AG: ODH announces its Egyptian Subsidiary (ODE)1Q 2021 Financial Results

EQS-Adhoc: Orascom Development Holding AG: ODH announces its Egyptian Subsidiary (ODE)1Q 2021 Financial Results Orascom Development Holding AG announces its Egyptian Subsidiary (ODE)1Q 2021 Financial Results 10-May-2021 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 KR The issuer is solely responsible for the content of this announcement. Dear All, Orascom Development Egypt (ODE); the Largest Egyptian Subsidiary of Orascom Development Holding AG (ODH), has reported its 1Q 2021 earnings today. Please find the earnings release along with the presentation under the link ...

Junshi Biosciences and Coherus Announce Toripalimab First-Line Nasopharyngeal Carcinoma Clinical Data to be Showcased in Plenary Session at 2021 ASCO Annual Meeting - Vimarsana News

Junshi Biosciences and Coherus Announce Toripalimab First-Line Nasopharyngeal Carcinoma Clinical Data to be Showcased in Plenary Session at 2021 ASCO Annual Meeting

- Toripalimab data will also be featured in ASCO's official press program -SHANGHAI, China, and REDWOOD CITY, Calif., April 29, 2021 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd. ("Junshi Biosciences"

Investegate |Junshi Biosciences Announcements | Junshi Biosciences: Junshi Biosciences and Coherus Announce Toripalimab First-Line Nasopharyngeal Carcinoma Clinical Data to be Showcased in Plenary Session at 2021 ASCO Annual Meeting - Vimarsana News

Investegate |Junshi Biosciences Announcements | Junshi Biosciences: Junshi Biosciences and Coherus Announce Toripalimab First-Line Nasopharyngeal Carcinoma Clinical Data to be Showcased in Plenary Session at 2021 ASCO Annual Meeting

June 3, 2021, 5:00 p.m. Eastern Daylight Time “We are excited that results of JUPITER-02, a Phase 3 clinical trial evaluating toripalimab plus chemotherapy for the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma, have been selected for presentation during ASCO’s plenary session, which traditionally features high-impact studies,” said Dr. Patricia Keegan, Chief Medical Officer of Junshi Biosciences. “Treatment of nasopharyngeal carcinoma, a specific type of head-and-neck cancer, is challenging, as the diagnosis usually occurs when the cancer is in an advanced s...